Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Updates FY17 Earnings Guidance

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus estimate of $11.02. The company issued revenue guidance of $1.625-1.7 billion, compared to the consensus revenue estimate of $1.66 billion.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded down 1.10% during trading on Friday, reaching $144.40. The company had a trading volume of 1,596,250 shares. The stock’s 50-day moving average price is $153.33 and its 200-day moving average price is $147.61. The stock has a market capitalization of $8.67 billion, a PE ratio of 22.24 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same quarter last year, the company posted $2.67 EPS. Jazz Pharmaceuticals PLC’s revenue was up 3.5% on a year-over-year basis. Equities analysts forecast that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current fiscal year.

A number of brokerages have recently commented on JAZZ. Zacks Investment Research downgraded Jazz Pharmaceuticals PLC from a hold rating to a sell rating in a research report on Tuesday, May 2nd. Royal Bank Of Canada set a $210.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a buy rating in a research note on Tuesday, June 27th. Cantor Fitzgerald reissued a buy rating and set a $197.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, June 27th. Cowen and Company reissued an outperform rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, May 10th. Finally, Leerink Swann set a $179.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a buy rating in a research note on Thursday, April 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of $182.72.

In other Jazz Pharmaceuticals PLC news, Director Paul L. Berns sold 662 shares of the stock in a transaction on Friday, August 11th. The shares were sold at an average price of $142.37, for a total transaction of $94,248.94. Following the transaction, the director now directly owns 6,599 shares of the company’s stock, valued at $939,499.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Suzanne Sawochka Hooper sold 420 shares of the stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $160.00, for a total transaction of $67,200.00. The disclosure for this sale can be found here. Insiders have sold 12,566 shares of company stock worth $1,921,138 over the last three months. Company insiders own 4.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2017/08/19/jazz-pharmaceuticals-plc-nasdaqjazz-updates-fy17-earnings-guidance-updated.html.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

What are top analysts saying about Jazz Pharmaceuticals PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jazz Pharmaceuticals PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit